IN VIVO DETECTION OF AMYLOID DEPOSITION USING F AGNETIC RESONANCE IMAGING WITH A F-CONTAINING CURCUMIN DERIVATIVE IN A MOUSE MODEL OF ALZHEIMER’S DISEASE

[1]  Shigehiro Morikawa,et al.  Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer's disease. , 2010, Biomaterials.

[2]  J. Salvador,et al.  The dark side of curcumin , 2010, International journal of cancer.

[3]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[4]  Anna Moore,et al.  Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. , 2009, Journal of the American Chemical Society.

[5]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[6]  C. Mancuso,et al.  Curcumin in clinical practice: myth or reality? , 2009, Trends in pharmacological sciences.

[7]  S. Morikawa,et al.  Trifluoromethoxy-benzylated ligands improve amyloid detection in the brain using 19F magnetic resonance imaging , 2009, Neuroscience Research.

[8]  J. Pettegrew,et al.  Clinically Relevant Concentration Determination of Inhaled Anesthetics (Halothane, Isoflurane, Sevoflurane, and Desflurane) by 19F NMR , 2008, Cell Biochemistry and Biophysics.

[9]  M. Garwood,et al.  Selective Contrast Enhancement of Individual Alzheimer’s Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar Aβ42 for Magnetic Resonance Molecular Imaging , 2008, Pharmaceutical Research.

[10]  B. Aggarwal,et al.  Curcumin as "Curecumin": from kitchen to clinic. , 2008, Biochemical pharmacology.

[11]  V. Mok,et al.  Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. , 2008, Journal of clinical psychopharmacology.

[12]  M. Ramirez-Alvarado,et al.  In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques , 2007, Journal of neurochemistry.

[13]  Kazuhiko Yanai,et al.  2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.

[14]  K. Takata,et al.  Microglial transplantation increases amyloid‐β clearance in Alzheimer model rats , 2007 .

[15]  Eun Kyoung Ryu,et al.  Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. , 2006, Journal of medicinal chemistry.

[16]  Y. Kitamura,et al.  Comparison of MR images and histochemical localization of intra-arterially administered microglia surrounding beta-amyloid deposits in the rat brain. , 2006, Histology and histopathology.

[17]  Nobuhisa Iwata,et al.  19F and 1H MRI detection of amyloid β plaques in vivo , 2005, Nature Neuroscience.

[18]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[19]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[20]  Agneta Nordberg,et al.  PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.

[21]  G. Curran,et al.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. , 2004, Biochemistry.

[22]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[23]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[24]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[25]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer Research.

[26]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[27]  V. Simplaceanu,et al.  Intravenous anesthetic diazepam does not induce amyloid-beta peptide oligomerization but diazepam co-administered with halothane oligomerizes amyloid-beta peptide: an NMR study. , 2010, Journal of Alzheimer's disease : JAD.

[28]  D. Yanagisawa,et al.  Amyloid imaging using high-field magnetic resonance. , 2010, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[29]  P. Mandal,et al.  NMR investigations of amyloid-β peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. , 2010, Journal of Alzheimer's disease : JAD.